Alnylam Pharmaceuticals
ALNY
#634
Rank
โ‚ฌ30.37 B
Marketcap
235,52ย โ‚ฌ
Share price
-0.80%
Change (1 day)
57.10%
Change (1 year)
Alnylam Pharmaceuticals Inc. is a biopharmaceutical company focused on the R&D and commercialization of RNA interference (RNAi) therapeutics for genetically defined diseases.

EPS for Alnylam Pharmaceuticals (ALNY)

EPS in 2023 (TTM): -3,77ย โ‚ฌ

According to Alnylam Pharmaceuticals 's latest financial reports the company's current EPS (TTM) is -3,92ย โ‚ฌ. In 2022 the company made an earnings per share (EPS) of -8,87ย โ‚ฌ a decrease over its 2021 EPS that were of -6,87ย โ‚ฌ.

EPS history for Alnylam Pharmaceuticals from 2003 to 2023

Annual EPS

Year EPS Change
2023 (TTM)-3,77ย โ‚ฌ-57.49%
2022-8,87ย โ‚ฌ29.03%
2021-6,87ย โ‚ฌ-3.36%
2020-7,11ย โ‚ฌ-8.48%
2019-7,77ย โ‚ฌ7.67%
2018-7,21ย โ‚ฌ39.74%
2017-5,16ย โ‚ฌ12.94%
2016-4,57ย โ‚ฌ38.84%
2015-3,29ย โ‚ฌ-32.88%
2014-4,91ย โ‚ฌ259.44%
2013-1,36ย โ‚ฌ-31.25%
2012-1,98ย โ‚ฌ52.94%
2011-1,30ย โ‚ฌ30.77%
2010-0,99ย โ‚ฌ-8.77%
2009-1,09ย โ‚ฌ78.13%
2008-0,61ย โ‚ฌ-70.78%
2007-2,09ย โ‚ฌ99.09%
2006-1,05ย โ‚ฌ-43.88%
2005-1,87ย โ‚ฌ-82.33%
2004-10,59ย โ‚ฌ-59.23%
2003-25,97ย โ‚ฌ

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
-1,62ย โ‚ฌ-58.64%๐Ÿ‡บ๐Ÿ‡ธ USA
35,65ย โ‚ฌ-1,009.00%๐Ÿ‡บ๐Ÿ‡ธ USA
-7,47ย โ‚ฌ 90.51%๐Ÿ‡บ๐Ÿ‡ธ USA
-0,26ย โ‚ฌ-93.43%๐Ÿ‡บ๐Ÿ‡ธ USA
-1,61ย โ‚ฌ-58.88%๐Ÿ‡บ๐Ÿ‡ธ USA
3,57ย โ‚ฌ-191.00%๐Ÿ‡จ๐Ÿ‡ญ Switzerland
3,03ย โ‚ฌ-177.38%๐Ÿ‡ซ๐Ÿ‡ท France
-1,91ย โ‚ฌ-51.34%๐Ÿ‡ฎ๐Ÿ‡ฑ Israel